ResearchSpeak: ECTRIMS 2015

Are you ready for ECTRIMS 2015? #ECTRIMS #ReasearchSpeak #MSBlog #MSResearch

"I am sitting in the departure lounge at Heathrow ready to fly to Barcelona for the ECTRIMS 2015 meeting. Slight flutter of anxiety and anticipation; this meeting promises to the best ECTRIMS yet in relation to new data being presented. I am very excited about the ocrelizumab phase 3 data, both in the relapsing and primary progressive MS. Data will also be presented on baseline cognitive function as an important predictor of outcome; this will add impetus for incorporating cognitive  function testing into routine clinical practice. Follow-on data will be presented on the impact of alemtuzumab and other DMTs on end-organ damage (brain atrophy); the alemtuzumab brain atrophy data is possibly too good to be true."

"Barts-MS will be very active over the week; we promise to keep you all informed. I am looking forward to the launch of our policy document, that is trying  to shift the focus of MS treatment to focus on brain health, to stress that 'time matters' and to manage MS holistically. Hopefully all the questions and issues raised by our recent posts on early vs. delayed treatment will be addressed in the document. The next challenge is to get our neurology colleagues and other stakeholders to read the document and to get policymakers to adopt and implement the core principles being espoused."

"My diary is a sea of blue; I have never been busier at a meeting. I am not complaining it is all for a good cause, hopefully to make the lives of MSers and their families easier."

Scientific Programme ECTRIMS 2015 from Gavin Giovannoni

Labels: ,